share_log

DexCom | 10-Q: Q2 2024 Earnings Report

DexCom | 10-Q: Q2 2024 Earnings Report

德康医疗 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/07/25 17:19

Moomoo AI 已提取核心信息

DexCom reported strong Q2 2024 financial results with revenue reaching $1.00 billion, up 15% year-over-year, driven by increased sales volume of disposable sensors. Net income rose 24% to $143.5 million, while operating income grew 23% to $158.0 million. Gross profit increased 15% to $626.7 million with a 62.4% margin.The company's growth was primarily fueled by its expanding worldwide customer base, having added approximately 600,000 net users in 2023. U.S. revenue grew 19% to $731.9 million, representing 73% of total revenue, while international revenue increased 7% to $272.4 million. Disposable sensor and other revenue comprised 94% of total revenue, up from 89% in the prior year period.Looking ahead, DexCom maintains strong liquidity with $3.12 billion in cash and investments. The company announced a new $750 million share repurchase program through June 2025, demonstrating confidence in its financial position. Management continues to focus on expanding global operations through investments in manufacturing facilities in Malaysia and Ireland to meet growing product demand.
DexCom reported strong Q2 2024 financial results with revenue reaching $1.00 billion, up 15% year-over-year, driven by increased sales volume of disposable sensors. Net income rose 24% to $143.5 million, while operating income grew 23% to $158.0 million. Gross profit increased 15% to $626.7 million with a 62.4% margin.The company's growth was primarily fueled by its expanding worldwide customer base, having added approximately 600,000 net users in 2023. U.S. revenue grew 19% to $731.9 million, representing 73% of total revenue, while international revenue increased 7% to $272.4 million. Disposable sensor and other revenue comprised 94% of total revenue, up from 89% in the prior year period.Looking ahead, DexCom maintains strong liquidity with $3.12 billion in cash and investments. The company announced a new $750 million share repurchase program through June 2025, demonstrating confidence in its financial position. Management continues to focus on expanding global operations through investments in manufacturing facilities in Malaysia and Ireland to meet growing product demand.
德康医疗发布了2024年第二季度强劲的财务业绩，营业收入达到10亿美金，同比增长15%，主要得益于一次性传感器的销售量增加。净利润上涨24%，达到14350万美元，而营业利润增长23%，达到15800万美元。毛利润增加15%，达到62670万美元，利润率为62.4%。公司的增长主要得益于其全球客户基础的扩展，2023年净用户数增加了约600,000人。美国的营业收入增长19%，达到73190万美元，占总营业收入的73%，而国际营业收入增长7%，达到27240万美元。一一次性传感器和其他收入占总收入的94%，高于去年同期的89%。展望未来，德康医疗保持强劲的流动性，现金和投资总额为31.2亿美金。公司宣布了一项新的75000万美元的股票回购计划，直到2025年6月，显示出对其财务状况的信心。管理层继续专注于通过在马来西亚和爱尔兰投资制造设施来扩大全球业务，以满足日益增长的产品需求。
德康医疗发布了2024年第二季度强劲的财务业绩，营业收入达到10亿美金，同比增长15%，主要得益于一次性传感器的销售量增加。净利润上涨24%，达到14350万美元，而营业利润增长23%，达到15800万美元。毛利润增加15%，达到62670万美元，利润率为62.4%。公司的增长主要得益于其全球客户基础的扩展，2023年净用户数增加了约600,000人。美国的营业收入增长19%，达到73190万美元，占总营业收入的73%，而国际营业收入增长7%，达到27240万美元。一一次性传感器和其他收入占总收入的94%，高于去年同期的89%。展望未来，德康医疗保持强劲的流动性，现金和投资总额为31.2亿美金。公司宣布了一项新的75000万美元的股票回购计划，直到2025年6月，显示出对其财务状况的信心。管理层继续专注于通过在马来西亚和爱尔兰投资制造设施来扩大全球业务，以满足日益增长的产品需求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日